Forecast: Basic Pharmaceutical Products and Pharmaceutical Preparations Turnover in France

The turnover for basic pharmaceutical products and pharmaceutical preparations in France saw a fluctuating yet generally positive trend between 2013 and 2023. Despite some dips, such as in 2015 and 2019, significant growth periods occurred, particularly between 2016 and 2017. By 2023, the sector stood at 44.64 billion Euros. The year-on-year growth rate for 2022-2023 was 1.09%, reflecting consistent, albeit modest, growth. The five-year CAGR leading up to 2023 was -0.52%, indicating that the market has experienced minor contractions at times.

Looking ahead, the forecast from 2024 to 2028 suggests a steady increase, with turnover expected to rise from 45.12 billion Euros in 2024 to 46.98 billion Euros by 2028. The forecast CAGR over these five years is projected to be 0.81%, highlighting sustainable growth.

Future trends to watch for:

• Advances in biotechnology and personalized medicine could drive growth.

• Regulatory changes and healthcare policy adjustments may impact market stability.

• Innovations in drug delivery and the rise of digital health solutions could reshape value propositions.

• Potential economic fluctuations and global health crises could influence market dynamics.